bioAffinity Technologies develops the CyPath® Lung test, a non-invasive diagnostic tool that utilizes flow cytometry to analyze sputum samples for early-stage lung cancer detection. This technology addresses the challenge of accurately diagnosing suspicious findings from low-dose computed tomography (LDCT), significantly improving diagnostic accuracy and reducing unnecessary invasive procedures.
Funding
$2.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Lung cancer screening using low-dose computed tomography (LDCT) often yields suspicious findings that require further investigation. However, the low positive predictive value of LDCT can lead to unnecessary invasive procedures, causing patient anxiety and increasing medical costs.
Solution
bioAffinity Technologies offers CyPath® Lung, a non-invasive diagnostic test that analyzes sputum samples using flow cytometry to detect early-stage lung cancer. The test profiles the lung micro-environment by characterizing cell populations indicative of cancer. By providing a more accurate assessment of suspicious LDCT results, CyPath® Lung helps clinicians make informed decisions, potentially reducing the need for unnecessary invasive procedures and improving patient outcomes. The test utilizes advanced flow cytometry and automated data analysis to identify cancer in the lung, with results available to physicians within three days of sample receipt.
Target Audience
The primary users are physicians who need to assess patients with suspicious, but indeterminate, LDCT results for lung cancer.
Features
- Non-invasive sputum collection using an at-home sample collection kit
- Advanced flow cytometry to profile the lung micro-environment
- Porphyrin labeling of cells to indicate the presence of cancer
- Automated data analysis for rapid results
- High sensitivity and specificity in detecting early-stage lung cancer in individuals at high risk with nodules less than 20mm
- Results available to physicians within three days
- CLIA-certified laboratory testing